Human CXADR/CAR Recombinant Protein (RPES1112)
- SKU:
- RPES1112
- Product Type:
- Recombinant Protein
- Species:
- Human
- Research Area:
- Cell Biology
Frequently bought together:
Description
system_update_altDatasheet
Human CXADR/CAR Recombinant Protein
CXADR is a gene that encodes a protein that belongs to the type I membrane receptor for group B coxsackieviruses and subgroup C adenoviruses. The CXADR gene has at least two distinct transcript variants, each of which yields several proteins. The chromosome numbers of pseudogenes of CXADR are 15, 18, and 21. Two examples of CXADR-related diseases are myocarditis and shipyard eye. The innate immune system and adhesion are two pathways that may be affected by CXADR. Human CXADR/CAR Recombinant Protein is a highly pure recombinant protein developed by Assay Genie for use in a range of applications.
Product Name: | Human CXADR/CAR Recombinant Protein (RPES1112) |
Product Code: | RPES1112 |
Size: | 10µg |
Species: | Human |
Expressed Host: | Human Cells |
Synonyms: | Coxsackievirus and Adenovirus Receptor, CAR, hCAR, CVB3-Binding Protein, Coxsackievirus B-Adenovirus Receptor, HCVADR, CXADR, CAR |
Accession: | P78310 |
Sequence: | Leu20-Gly237 |
Fusion tag: | C-6His |
Endotoxin: | <1.0 EU per µg as determined by the LAL method. |
Protein Construction: | Recombinant Human Coxsackievirus and Adenovirus Receptor is produced by our Mammalian expression system and the target gene encoding Leu20-Gly237 is expressed with a 6His tag at the C-terminus. |
Purity: | > 95 % as determined by reducing SDS-PAGE. |
Mol Mass: | 25.1 kDa |
AP Mol Mass: | 32 kDa |
Formulation: | Lyophilized from a 0.2 µm filtered solution of 20mM PB, 150mM NaCl, pH 7.2. |
Shipping: | This product is provided as lyophilized powder which is shipped with ice packs. |
Stability and Storage: | Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |